Table 1.

Basal Characteristics, Laboratory Test Results, and CUS Findings of Hospitalized Patients With COVID‐19 and PE

Patient	DVT	Sex Age, y	Obesity, BMI >30 kg/m2	History of VTE	Known Thrombophilia	Active Cancer	Days a	PE Location	Thromboprophylaxis on Admission	Oxygen Therapy	Lymphocytes, ×103/μL	Platelets, ×103/μL	Peak d‐Dimer, μg/dL	LDH, U/L	IL‐6, U/L	Ferritin, ng/dL	CRP, mg/dL
1	No	Male 65	35.3	No	No	No	28	Unilateral peripheral	Enoxaparin, 60 mg OD	Nasal cannula	2,500	286	24,880	277	123	538	0.4
2	No	Male 73	30.1	No	No	No	21	Bilateral peripheral	Enoxaparin, 40 mg OD	NIV	1,300	186	80,000	727	NA	NA	1
3	No	Male 75	NA	No	No	No	15	Bilateral peripheral	Enoxaparin, 40 mg OD	NIV	1,000	482	63,590	946	476	1,698	2.5
4	No	Male 73	27.3	No	No	No	1	Bilateral central	No prophylaxis	Nasal cannula	2,800	162	8,980	266	NA	420	0.9
5	No	Male 49	26.7	No	No	No	9	Bilateral central	Enoxaparin, 40 mg OD	NIV	1,300	349	35,200	950	NA	801	NA
6	No	Male 68	27.3	No	No	No	15	Unilateral peripheral	Enoxaparin, 60 mg OD	Nasal cannula	600	322	19,510	256	19.4	1,122	1.2
7	No	Male 56	24.6	No	No	No	9	Bilateral peripheral	Enoxaparin, 40 mg OD	High flow	500	540	45,350	480	NA	810	106
8	No	Female 58	26.9	No	No	No	8	Unilateral peripheral	Enoxaparin, 40 mg OD	High flow	1,000	370	14,940	408	486.0	461	NA
9	No	Female 37	27.3	No	No	No	12	Unilateral peripheral	No prophylaxis	No oxygen	1,800	240	1,400	151	NA	200	1
10	No	Male 58	32.4	No	No	No	20	Bilateral peripheral	Enoxaparin, 40 mg OD	Nasal cannula	1,300	455	26,160	245	NA	NA	30.6
11	No	Male 60	32.9	No	No	No	7	Unilateral peripheral	Enoxaparin, 40 mg OD	High flow	1,000	288	7,470	172	6.8	406	3.5
12	No	Female 78	26.2	No	No	No	9	Unilateral peripheral	No prophylaxis	High flow	700	548	5,530	319	6.1	3,565	267
13	No	Male 80	30.5	No	No	No	5	Unilateral central	Enoxaparin, 60 mg OD	High flow	4,500	234	28,740	253	5.8	1,373	53
14	No	Male 70	31.8	No	No	No	2	Bilateral central	Enoxaparin, 60 mg OD	NIV	1,000	207	80,000	619	93	1,389	470.7
15	No	Male 43	22.9	No	No	No	2	Bilateral peripheral	Enoxaparin, 80 mg OD	No oxygen	300	566	10,630	228	2.8	990	3.6
16	No	Female 67	32.3	No	No	No	0	Bilateral central	No prophylaxis	Nasal cannula	1,800	149	21,380	306	NA	NA	32.5
17	No	Female 75	19.7	No	No	No	12	Bilateral peripheral	Enoxaparin, 80 mg OD	Nasal cannula	600	149	47,970	283	NA	566	238.9
18	No	Female 81	33.3	No	No	No	3	Unilateral peripheral	No prophylaxis	Nasal cannula	1,000	230	5,540	248	NA	NA	5.3
19	No	Female 58	31.5	No	No	No	7	Bilateral peripheral	Enoxaparin, 60 mg OD	Nasal cannula	2,200	429	11,520	231	5.3	419	16.9
20	No	Male 54	24.9	No	No	No	0	Bilateral central	No prophylaxis	Nasal cannula	2,200	333	36,170	164	73.8	677	71
21	No	Male 60	25.3	No	No	No	0	Unilateral peripheral	No prophylaxis	Nasal cannula	1,500	302	1,210	139	66.4	754	157
22	No	Male 54	27.0	No	No	No	1	Bilateral peripheral	Enoxaparin, 60 mg OD	Nasal cannula	1,000	256	18,680	224	40.0	387	90.9
23	No	Female 54	NA	No	No	No	15	Unilateral peripheral	Enoxaparin, 80 mg OD	NIV	1,000	164	22,460	621	1001	1,807	27.3
24	No	Female 53	27.1	No	No	Yes	11	Unilateral peripheral	No prophylaxis	Nasal cannula	1,900	182	4,210	136	211	202	12.1
25	Yes	Female 68	33.5	No	No	No	0	Bilateral central	No prophylaxis	Nasal cannula	2,500	287	3,430	163	10	115	11.3
26	Yes	Female 56	21.8	No	No	No	0	Bilateral central	No prophylaxis	No oxygen	1,700	240	7,190	NA	NA	NA	126

BMI indicates body mass index; CRP, C‐reactive protein; IL‐6, interleukin‐6; LDH, lactate dehydrogenase; NA, not available; NIV, noninvasive ventilation; OD, once daily; and VTE, venous thromboembolism.

^a Days from admission to hospital to PE diagnosis. .